Anakin Protein as a Prognostic Tool for Diagnosing Breast Cancer Outcome
Available for collaborative research toward commercial
development and/or exclusive and non-exclusive
licensing:
- Method of diagnosis for early metastasis and
therapeutic inhibition of metastasis.
- Nucleic acid sequence of Anakin protein, an
extracellular matrix (ECM) modifier gene.
- SiRNA sequences that inhibit Anakin expression
as therapeutics. Purified antibodies that recognize Anakin protein
as a research reagent and in diagnostics related
products.
Recent evidence suggests that metastatic disease
can be an early event and in majority of patients metastasis starts
by the time the disease is diagnosed. Thus there is a need for
methods of characterizing the early metastatic process for better
treatment of cancer.
This invention provides methods of characterizing the metastatic
capacity of a tumor as well as inhibiting metastasis of a cancer
cell. More specifically, this invention discloses an extracellular
matrix (ECM) modifier protein named Anakin, detection of the Anakin
protein as a marker for metastatic disease and use of Anakin as
potential therapeutic target.
Development Status:
Pre-clinical
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #431 RW
Updated 10/24/2007
This opportunity is also listed under the following categories: